-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Systemic Lupus Erythematosus Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Head And...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Recurrent Head...
-
Product Insights
Galicia Wind Farm-EDP, Spain
Galicia Wind Farm-EDP is proposed to be built in Galicia, Spain. The project is at the permitting stage. Empower your strategies with our Galicia Wind Farm-EDP report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons...
-
Product Insights
NewNet Present Value Model: Enanta Pharmaceuticals Inc’s EDP-938
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EDP-938 in Respiratory Syncytial Virus (RSV) Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EDP-938 in Respiratory Syncytial Virus (RSV) Infections Drug Details: EP-938 is under development for the...
-
Sector Analysis
Spain Solar Photovoltaic (PV) Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
Spain Solar Photovoltaic (PV) Market Overview The cumulative installed capacity for solar PV in Spain was 29.97MW in 2022 and will achieve a CAGR of more than 15% during 2022-2035. In 2022, asset transactions deal type closed the majority of deals in Spain's solar photovoltaic market. Spain Solar PV Market Outlook, 2022-2035 Buy the Full Report for More Insights into Spain's Solar PV Market Forecast Download a Free Report Sample The report discusses the cumulative installed capacity, annual capacity addition, and...
-
Sector Analysis
Spain Wind Power Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
Spain Wind Power Market Report Overview In Spain’s renewable power generation mix, onshore was the dominant source in 2022, followed by solar PV and biopower respectively. The cumulative installed capacity for wind power in Spain was 30.18 GW in 2022 and will achieve a CAGR of more than 6% during 2022-2035. Spain Wind Power Market Outlook, 2022-2035 (GW) Buy the Full Report for More Insights into the Spain Wind Power Market Forecast Download a Free Report Sample The report discusses...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s ODM-208
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azenosertib in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Epithelial Ovarian Cancer Drug Details: Azenosertib (ZNC-3) is under...